0000899243-18-029124.txt : 20181116 0000899243-18-029124.hdr.sgml : 20181116 20181116160032 ACCESSION NUMBER: 0000899243-18-029124 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181115 FILED AS OF DATE: 20181116 DATE AS OF CHANGE: 20181116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROGERS MICHAEL W CENTRAL INDEX KEY: 0001244159 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 181189836 MAIL ADDRESS: STREET 1: C/O KERYX BIOPHARMACEUTICALS INC STREET 2: ONE MARINA PARK DRIVE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-15 0 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001244159 ROGERS MICHAEL W C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 1 0 0 0 Common Stock 2018-11-15 4 M 0 100000 1.13 A 112500 D Employee Stock Option (right to buy) 1.13 2018-11-15 4 M 0 100000 0.00 D 2009-11-18 2018-11-18 Common Stock 100000 0 D Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, /s/ John Mercer, Attorney-in-Fact 2018-11-16